Rucaparib Camsylate Suppliers & Bulk Manufacturers
Available Forms: Oral tablets
Available Strengths: 200 mg, 250 mg, 300 mg
Reference Brands: Rubraca® (EU & US)
Category:
Oncology Cancer Care
Rucaparib Camsylate is a PARP inhibitor used for treating ovarian, fallopian tube, and peritoneal cancers, particularly those with BRCA mutations. Marketed under Rubraca®, it is available in 200 mg, 250 mg, and 300 mg oral tablets. Manufactured in GMP-compliant facilities, Rucaparib offers a targeted approach to cancer treatment and is a reliable choice for pharmaceutical distributors in US and EU markets.
Rucaparib Camsylate is available in Oral tablets
and strengths such as 200 mg, 250 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rucaparib Camsylate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rucaparib Camsylate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rucaparib Camsylate is an innovative PARP inhibitor used in the treatment of ovarian, fallopian tube, and peritoneal cancers. This targeted therapy is especially effective in cancers with BRCA mutations, as it disrupts DNA repair mechanisms in cancer cells, leading to their destruction. Available under the brand name Rubraca®, it is offered in 200 mg, 250 mg, and 300 mg oral tablet strengths. Manufactured under GMP-certified conditions, Rucaparib is a trusted solution in oncology care. Ideal for US and EU pharmaceutical distributors and wholesalers, it provides an advanced treatment option in precision medicine for cancer patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing